[Skip to Content]
[Skip to Content Landing]

Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal CancerA Review

Educational Objective
To learn the safety and efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal metastases from epithelial ovarian cancer and colorectal cancer.
1 Credit CME
Abstract

Importance  The peritoneal surface is a common site of disease in ovarian and colorectal cancer. Peritoneal metastases carry a poor prognosis, despite maximal therapeutic efforts, including surgical removal of tumor deposits and intravenous chemotherapy. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a single intraoperative procedure that delivers chemotherapy directly into the abdominal cavity, leading to high intracellular drug concentration at the peritoneal surface. This review describes the current knowledge regarding the mechanism of action, safety, and efficacy of HIPEC in the treatment of peritoneal metastases from epithelial ovarian and colorectal cancers and explores current knowledge gaps.

Observations  Toxic effects of HIPEC are limited. Evidence from a randomized trial shows improved recurrence-free and overall survival after HIPEC in patients with ovarian cancer who are ineligible for primary cytoreductive surgery (CRS). The effect of HIPEC for patients with ovarian cancer undergoing primary CRS or CRS for recurrent disease has not yet been determined, and results of ongoing trials must be awaited. A recent study in patients with peritoneal metastases from colorectal cancer did not show a benefit of HIPEC when added to perioperative chemotherapy.

Conclusions and Relevance  Based on available evidence, various international guidelines include the option to add HIPEC to interval CRS for patients with stage III ovarian cancer. The role of HIPEC in colorectal cancer is less well defined. Future studies will need to tailor patient selection, timing, and optimal regimens of HIPEC to improve the effectiveness of this specialized treatment in ovarian, colorectal, and other tumor types.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: February 1, 2021.

Published Online: May 6, 2021. doi:10.1001/jamaoncol.2021.0580

Corresponding Author: Willemien J. van Driel, MD, PhD, Center for Gynecologic Oncology Amsterdam, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands (w.v.driel@nki.nl).

Author Contributions: Drs van Stein and van Driel had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: van Stein, Aalbers, Sonke.

Acquisition, analysis, or interpretation of data: van Stein, Aalbers, van Driel.

Drafting of the manuscript: van Stein, Aalbers.

Critical revision of the manuscript for important intellectual content: Aalbers, Sonke, van Driel.

Administrative, technical, or material support: van Stein, Aalbers.

Supervision: Aalbers, Sonke, van Driel.

Conflict of Interest Disclosures: Dr Sonke reported receiving institutional research support from AstraZeneca, Merck & Co, Inc, Novartis AG, and F. Hoffman–La Roche Ltd outside the scope of this review. No other disclosures were reported.

Additional Contributions: The Figure is reprinted with permission from LMC Vos, Netherlands Cancer Institute, all rights reserved.

References
1.
Brücher  BL , Piso  P , Verwaal  V ,  et al.  Peritoneal carcinomatosis: cytoreductive surgery and HIPEC—overview and basics.   Cancer Invest. 2012;30(3):209-224. doi:10.3109/07357907.2012.654871 PubMedGoogle ScholarCrossref
2.
Sadeghi  B , Arvieux  C , Glehen  O ,  et al.  Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.   Cancer. 2000;88(2):358-363. doi:10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O PubMedGoogle ScholarCrossref
3.
Sugarbaker  PH .  Peritonectomy procedures.   Surg Oncol Clin N Am. 2003;12(3):703-727, xiii. doi:10.1016/S1055-3207(03)00048-6PubMedGoogle ScholarCrossref
4.
Spratt  JS , Adcock  RA , Muskovin  M , Sherrill  W , McKeown  J .  Clinical delivery system for intraperitoneal hyperthermic chemotherapy.   Cancer Res. 1980;40(2):256-260.PubMedGoogle Scholar
5.
Dedrick  RL , Myers  CE , Bungay  PM , DeVita  VT  Jr .  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.   Cancer Treat Rep. 1978;62(1):1-11.PubMedGoogle Scholar
6.
van Baal  JO , Van de Vijver  KK , Nieuwland  R ,  et al.  The histophysiology and pathophysiology of the peritoneum.   Tissue Cell. 2017;49(1):95-105. doi:10.1016/j.tice.2016.11.004 PubMedGoogle ScholarCrossref
7.
Flessner  MF , Dedrick  RL , Schultz  JS .  A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat.   Am J Physiol. 1985;248(3, pt 2):F413-F424. doi:10.1152/ajprenal.1985.248.3.F413 PubMedGoogle Scholar
8.
Dedrick  RL , Flessner  MF .  Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.   J Natl Cancer Inst. 1997;89(7):480-487. doi:10.1093/jnci/89.7.480 PubMedGoogle ScholarCrossref
9.
Torres  IJ , Litterst  CL , Guarino  AM .  Transport of model compounds across the peritoneal membrane in the rat.   Pharmacology. 1978;17(6):330-340. doi:10.1159/000136874 PubMedGoogle ScholarCrossref
10.
Sugarbaker  PH , Van der Speeten  K .  Surgical technology and pharmacology of hyperthermic perioperative chemotherapy.   J Gastrointest Oncol. 2016;7(1):29-44.PubMedGoogle Scholar
11.
Elekonawo  FMK , van Eden  WJ , van der Plas  WY ,  et al.  Effect of intraperitoneal chemotherapy concentration on morbidity and survival.   BJS Open. 2020;4(2):293-300. doi:10.1002/bjs5.50250 PubMedGoogle ScholarCrossref
12.
Cashin  PH , Ehrsson  H , Wallin  I , Nygren  P , Mahteme  H .  Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis.   Eur J Clin Pharmacol. 2013;69(3):533-540. doi:10.1007/s00228-012-1405-4 PubMedGoogle ScholarCrossref
13.
Dyson  JE , Simmons  DM , Daniel  J , McLaughlin  JM , Quirke  P , Bird  CC .  Kinetic and physical studies of cell death induced by chemotherapeutic agents or hyperthermia.   Cell Tissue Kinet. 1986;19(3):311-324. doi:10.1111/j.1365-2184.1986.tb00683.x PubMedGoogle Scholar
14.
Hildebrandt  B , Wust  P , Ahlers  O ,  et al.  The cellular and molecular basis of hyperthermia.   Crit Rev Oncol Hematol. 2002;43(1):33-56. doi:10.1016/S1040-8428(01)00179-2 PubMedGoogle ScholarCrossref
15.
Multhoff  G , Mizzen  L , Winchester  CC ,  et al.  Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells.   Exp Hematol. 1999;27(11):1627-1636. doi:10.1016/S0301-472X(99)00104-6 PubMedGoogle ScholarCrossref
16.
Los  G , Smals  OA , van Vugt  MJ ,  et al.  A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.   Cancer Res. 1992;52(5):1252-1258.PubMedGoogle Scholar
17.
van de Vaart  PJ , van der Vange  N , Zoetmulder  FA ,  et al.  Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.   Eur J Cancer. 1998;34(1):148-154. doi:10.1016/S0959-8049(97)00370-5 PubMedGoogle ScholarCrossref
18.
Oei  AL , Vriend  LE , Crezee  J , Franken  NA , Krawczyk  PM .  Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all.   Radiat Oncol. 2015;10(1):165. doi:10.1186/s13014-015-0462-0 PubMedGoogle ScholarCrossref
19.
Krawczyk  PM , Eppink  B , Essers  J ,  et al.  Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.   Proc Natl Acad Sci U S A. 2011;108(24):9851-9856. doi:10.1073/pnas.1101053108 PubMedGoogle ScholarCrossref
20.
Kuijpers  AM , Hauptmann  M , Aalbers  AG ,  et al.  Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed.   Eur J Surg Oncol. 2016;42(2):244-250. doi:10.1016/j.ejso.2015.08.162 PubMedGoogle ScholarCrossref
21.
Kyriazanos  I , Kalles  V , Stefanopoulos  A , Spiliotis  J , Mohamed  F .  Operating personnel safety during the administration of hyperthermic intraperitoneal chemotherapy (HIPEC).   Surg Oncol. 2016;25(3):308-314. doi:10.1016/j.suronc.2016.06.001 PubMedGoogle ScholarCrossref
22.
Helderman  RFCPA , Löke  DR , Kok  HP ,  et al.  Variation in clinical application of hyperthermic intraperitoneal chemotherapy: a review.   Cancers (Basel). 2019;11(1):E78. doi:10.3390/cancers11010078 PubMedGoogle Scholar
23.
Esquivel  J , Averbach  A .  Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin.   Gastroenterol Res Pract. 2012;2012:981245. doi:10.1155/2012/981245 PubMedGoogle Scholar
24.
Klaver  CEL , Wisselink  DD , Punt  CJA ,  et al; COLOPEC Collaborators Group.  Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.   Lancet Gastroenterol Hepatol. 2019;4(10):761-770. doi:10.1016/S2468-1253(19)30239-0 PubMedGoogle ScholarCrossref
25.
Bray  F , Ferlay  J , Soerjomataram  I , Siegel  RL , Torre  LA , Jemal  A .  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.   CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 PubMedGoogle ScholarCrossref
26.
Timmermans  M , Sonke  GS , Van de Vijver  KK , van der Aa  MA , Kruitwagen  RFPM .  No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands.   Eur J Cancer. 2018;88:31-37. doi:10.1016/j.ejca.2017.10.030 PubMedGoogle ScholarCrossref
27.
Doubeni  CA , Doubeni  AR , Myers  AE .  Diagnosis and management of ovarian cancer.   Am Fam Physician. 2016;93(11):937-944.PubMedGoogle Scholar
28.
Vergote  I , Tropé  CG , Amant  F ,  et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.   N Engl J Med. 2010;363(10):943-953. doi:10.1056/NEJMoa0908806 PubMedGoogle ScholarCrossref
29.
Wright  AA , Bohlke  K , Armstrong  DK ,  et al.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline.   J Clin Oncol. 2016;34(28):3460-3473. doi:10.1200/JCO.2016.68.6907 PubMedGoogle ScholarCrossref
30.
Moore  K , Colombo  N , Scambia  G ,  et al.  Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.   N Engl J Med. 2018;379(26):2495-2505. doi:10.1056/NEJMoa1810858 PubMedGoogle ScholarCrossref
31.
González-Martín  A , Pothuri  B , Vergote  I ,  et al; PRIMA/ENGOT-OV26/GOG-3012 Investigators.  Niraparib in patients with newly diagnosed advanced ovarian cancer.   N Engl J Med. 2019;381(25):2391-2402. doi:10.1056/NEJMoa1910962 PubMedGoogle ScholarCrossref
32.
Armstrong  DK , Bundy  B , Wenzel  L ,  et al; Gynecologic Oncology Group.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.   N Engl J Med. 2006;354(1):34-43. doi:10.1056/NEJMoa052985 PubMedGoogle ScholarCrossref
33.
Wright  AA , Cronin  A , Milne  DE ,  et al.  Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer.   J Clin Oncol. 2015;33(26):2841-2847. doi:10.1200/JCO.2015.61.4776 PubMedGoogle ScholarCrossref
34.
Tewari  D , Java  JJ , Salani  R ,  et al.  Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study.   J Clin Oncol. 2015;33(13):1460-1466. doi:10.1200/JCO.2014.55.9898 PubMedGoogle ScholarCrossref
35.
Jaaback  K , Johnson  N , Lawrie  TA .  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.   Cochrane Database Syst Rev. 2016;(1):CD005340. doi:10.1002/14651858.CD005340.pub4PubMedGoogle Scholar
36.
Walker  JL , Armstrong  DK , Huang  HQ ,  et al.  Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study.   Gynecol Oncol. 2006;100(1):27-32. doi:10.1016/j.ygyno.2005.11.013 PubMedGoogle ScholarCrossref
37.
Walker  JL , Brady  MF , Wenzel  L ,  et al.  Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group study.   J Clin Oncol. 2019;37(16):1380-1390. doi:10.1200/JCO.18.01568 PubMedGoogle ScholarCrossref
38.
van Driel  WJ , Koole  SN , Sikorska  K ,  et al.  Hyperthermic intraperitoneal chemotherapy in ovarian cancer.   N Engl J Med. 2018;378(3):230-240. doi:10.1056/NEJMoa1708618 PubMedGoogle ScholarCrossref
39.
Lim  MC , Chang  S-J , Yoo  HJ ,  et al.  Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer.   J Clin Oncol. 2017;35(15 suppl):5520. doi:10.1200/JCO.2017.35.15_suppl.5520 Google Scholar
40.
Zivanovic  O , Abramian  A , Kullmann  M ,  et al.  HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.   Int J Cancer. 2015;136(3):699-708.PubMedGoogle Scholar
41.
Howell  SB , Pfeifle  CL , Wung  WE ,  et al.  Intraperitoneal cisplatin with systemic thiosulfate protection.   Ann Intern Med. 1982;97(6):845-851. doi:10.7326/0003-4819-97-6-845 PubMedGoogle ScholarCrossref
42.
Koole  SN , Kieffer  JM , Sikorska  K ,  et al.  Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.   Eur J Surg Oncol. 2021;47(1):101-107. doi:10.1016/j.ejso.2019.05.006 PubMedGoogle ScholarCrossref
43.
Ceresoli  M , Verrengia  A , Montori  G ,  et al.  Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.   J Gynecol Oncol. 2018;29(3):e53. doi:10.3802/jgo.2018.29.e53 PubMedGoogle Scholar
44.
Koole  S , van Stein  R , Sikorska  K ,  et al; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group.  Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.   Int J Gynecol Cancer. 2020;30(6):888-892. doi:10.1136/ijgc-2020-001231 PubMedGoogle ScholarCrossref
45.
Bois  AD , Sehouli  J , Vergote  I ,  et al  Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20.   J Clin Oncol. 2020;38(15 suppl):6000. doi:10.1200/JCO.2020.38.15_suppl.6000Google Scholar
46.
Spiliotis  J , Halkia  E , Lianos  E ,  et al.  Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.   Ann Surg Oncol. 2015;22(5):1570-1575. doi:10.1245/s10434-014-4157-9 PubMedGoogle ScholarCrossref
47.
Harter  P , Reuss  A , Sehouli  J , Chiva  L , du Bois  A .  Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al.   Int J Gynecol Cancer. 2017;27(2):246-247. doi:10.1097/IGC.0000000000000864 PubMedGoogle ScholarCrossref
48.
ClinicalTrials.gov. Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment (CHIPOR). NCT01376752. Accessed February 1, 2021. https://clinicaltrials.gov/ct2/show/NCT01376752
49.
Koole  SN , Bruijs  L , Fabris  C ,  et al.  Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.   Int J Gynecol Cancer. 2020;30(12):1928-1934. doi:10.1136/ijgc-2020-001825 PubMedGoogle ScholarCrossref
50.
Koole  SN , van Driel  WJ , Sonke  GS .  Hyperthermic intraperitoneal chemotherapy for ovarian cancer: the heat is on.   Cancer. 2019;125(suppl 24):4587-4593. doi:10.1002/cncr.32505 PubMedGoogle ScholarCrossref
51.
Armstrong  DK , Alvarez  RD , Bakkum-Gamez  JN ,  et al.  NCCN guidelines insights: ovarian cancer, version 1.2019: featured updates to the NCCN guidelines.   J Natl Compr Canc Netw. 2019;17(8):896-909. doi:10.6004/jnccn.2019.0039PubMedGoogle ScholarCrossref
52.
Auer  RC , Sivajohanathan  D , Biagi  J , Conner  J , Kennedy  E , May  T .  Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.   Curr Oncol. 2020;27(3):146-154. doi:10.3747/co.27.6033PubMedGoogle ScholarCrossref
53.
Hoppenot  C , Schuitevoerder  D , Izquierdo  FJ ,  et al; Chicago Consensus Working Group.  The Chicago Consensus on Peritoneal Surface Malignancies: management of ovarian neoplasms.   Ann Surg Oncol. 2020;27(6):1780-1787. doi:10.1245/s10434-020-08322-y PubMedGoogle Scholar
54.
Colombo  N , Sessa  C , Bois  AD ,  et al; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.  Published online May 2, 2019.  Int J Gynecol Cancer. doi:10.1136/ijgc-2019-000308PubMedGoogle Scholar
55.
Koole  SN , van Lieshout  C , van Driel  WJ ,  et al.  Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial.   J Clin Oncol. 2019;37(23):2041-2050. doi:10.1200/JCO.19.00594 PubMedGoogle ScholarCrossref
56.
Segelman  J , Granath  F , Holm  T , Machado  M , Mahteme  H , Martling  A .  Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.   Br J Surg. 2012;99(5):699-705. doi:10.1002/bjs.8679 PubMedGoogle ScholarCrossref
57.
Franko  J , Shi  Q , Meyers  JP ,  et al; Analysis and Research in Cancers of the Digestive System (ARCAD) Group.  Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.   Lancet Oncol. 2016;17(12):1709-1719. doi:10.1016/S1470-2045(16)30500-9 PubMedGoogle ScholarCrossref
58.
Razenberg  LG , van Gestel  YR , Lemmens  VE , de Hingh  IH , Creemers  GJ .  Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study.   Clin Colorectal Cancer. 2016;15(2):e41-e46. doi:10.1016/j.clcc.2015.12.006 PubMedGoogle ScholarCrossref
59.
Esquivel  J , Lowy  AM , Markman  M ,  et al.  The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis.   Ann Surg Oncol. 2014;21(13):4195-4201. doi:10.1245/s10434-014-3798-z PubMedGoogle ScholarCrossref
60.
Verwaal  VJ , van Ruth  S , de Bree  E ,  et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.   J Clin Oncol. 2003;21(20):3737-3743. doi:10.1200/JCO.2003.04.187 PubMedGoogle ScholarCrossref
61.
Baratti  D , Kusamura  S , Pietrantonio  F , Guaglio  M , Niger  M , Deraco  M .  Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015: a systematic review.   Crit Rev Oncol Hematol. 2016;100:209-222. doi:10.1016/j.critrevonc.2016.01.017 PubMedGoogle ScholarCrossref
62.
Goéré  D , Glehen  O , Quenet  F ,  et al; BIG-RENAPE group.  Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (ProphyloCHIP-PRODIGE 15): a randomised, phase 3 study.   Lancet Oncol. 2020;21(9):1147-1154. doi:10.1016/S1470-2045(20)30322-3 PubMedGoogle ScholarCrossref
63.
ClinicalTrials.gov. Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma (HIPECT4). NCT02614534. Accessed February 1, 2021. https://clinicaltrials.gov/ct2/show/NCT02614534
64.
ClinicalTrials.gov. Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases (COLOPEC-II). NCT03413254. Accessed February 1, 2021. https://clinicaltrials.gov/ct2/show/NCT03413254
65.
Klaver  CE , Groenen  H , Morton  DG , Laurberg  S , Bemelman  WA , Tanis  PJ ; research committee of the European Society of Coloproctology.  Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines.   Colorectal Dis. 2017;19(3):224-236. doi:10.1111/codi.13593 PubMedGoogle ScholarCrossref
66.
Bushati  M , Rovers  KP , Sommariva  A ,  et al.  The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).   Eur J Surg Oncol. 2018;44(12):1942-1948. doi:10.1016/j.ejso.2018.07.003 PubMedGoogle ScholarCrossref
67.
Quénet  F , Elias  D , Roca  L ,  et al; UNICANCER-GI Group and BIG Renape Group.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.   Lancet Oncol. 2021;22(2):256-266. doi:10.1016/S1470-2045(20)30599-4 PubMedGoogle ScholarCrossref
68.
Rovers  KP , Bakkers  C , Simkens  GAAM ,  et al; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).  Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).   BMC Cancer. 2019;19(1):390. doi:10.1186/s12885-019-5545-0 PubMedGoogle ScholarCrossref
69.
Nagourney  RA , Evans  S , Tran  PH , Nagourney  AJ , Sugarbaker  PH .  Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.  Published online September 19, 2020.  Eur J Surg Oncol. doi:10.1016/j.ejso.2020.09.017 PubMedGoogle Scholar
70.
Hompes  D , D’Hoore  A , Wolthuis  A ,  et al.  The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.   J Surg Oncol. 2014;109(6):527-532. doi:10.1002/jso.23546 PubMedGoogle ScholarCrossref
71.
van Eden  WJ , Kok  NFM , Woensdregt  K , Huitema  ADR , Boot  H , Aalbers  AGJ .  Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.   Eur J Surg Oncol. 2018;44(2):220-227. doi:10.1016/j.ejso.2017.10.216 PubMedGoogle ScholarCrossref
72.
Prada-Villaverde  A , Esquivel  J , Lowy  AM ,  et al.  The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.   J Surg Oncol. 2014;110(7):779-785. doi:10.1002/jso.23728 PubMedGoogle ScholarCrossref
73.
Leung  V , Huo  YR , Liauw  W , Morris  DL .  Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.   Eur J Surg Oncol. 2017;43(1):144-149. doi:10.1016/j.ejso.2016.09.015 PubMedGoogle ScholarCrossref
74.
Bakkers  C , van Erning  FN , Rovers  KP ,  et al.  Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study.   Eur J Surg Oncol. 2020;46(10, pt A):1902-1907. doi:10.1016/j.ejso.2020.04.018 PubMedGoogle ScholarCrossref
75.
Ubink  I , Bolhaqueiro  ACF , Elias  SG ,  et al.  Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.   Br J Surg. 2019;106(10):1404-1414. doi:10.1002/bjs.11206 PubMedGoogle ScholarCrossref
76.
Goéré  D , Souadka  A , Faron  M ,  et al.  Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study.   Ann Surg Oncol. 2015;22(9):2958-2964. doi:10.1245/s10434-015-4387-5 PubMedGoogle ScholarCrossref
77.
Kwakman  R , Schrama  AM , van Olmen  JP ,  et al.  Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis.   Ann Surg. 2016;263(6):1102-1111. doi:10.1097/SLA.0000000000001593 PubMedGoogle ScholarCrossref
78.
Ubink  I , van Eden  WJ , Snaebjornsson  P ,  et al.  Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.   Br J Surg. 2018;105(2):e204-e211. doi:10.1002/bjs.10788 PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close